ROBOSENSE
20.9.2019 15:32:12 CEST | Business Wire | Press release
On September 18, 2019, RoboSense announced at Brussels, Belgium that its flagship product RS-LiDAR-M1 Smart LiDAR Sensor has been awarded the elite AutoSens Awards trophy in the “Best Automotive Safety System” category, given to only the highest-rated innovative product or technology in the automotive industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190920005309/en/
True autonomous driving requires human-like advanced sensing of the environment for driving with little or no human input. The safety of passengers and passers-by is always the priority concern for autonomous driving. When the RS-LiDAR-M1 is integrated into the current autonomous driving car perception system, it overcomes the weaknesses of millimeter wave radar and camera technologies on identifying obstacles, and eliminates car accidents, such as Tesla’s recent cases, greatly improving the security of autonomous driving and ensuring passenger safety.
The RS-LiDAR-M1 is the world’s first and only all-in-one unit MEMS-based smart LiDAR sensor for self-driving passenger vehicles with its own embedded AI algorithm technologies and SoC (System of Chip) . The RS-LiDAR-M1 transforms traditional LiDAR systems (also known as solely data collectors), to full data analysis and comprehension systems.
As a ground-breaking product, the RS-LiDAR-M1 not only collects and interprets high definition 3D point cloud data, but the RS-LiDAR-M1’s built-in AI algorithm and SoC also process road data in real-time, while at the same time synchronizing outputs of high-precision localization, obstacle detection, tracking and classification, road curbs and driving areas detection.
RS-LiDAR-M1’s built-in AI algorithm has went through a large number of extreme and complex environmental tests, such as a variety of road, weather, and traffic conditions, not only in simple situations such as highways, but also with complex challenges such as intersections with Chinese characters during peak commuting hours and dense traffic, in order to ensure that the Smart LiDAR Sensor can provide rich, precise, reliable and redundant information to the self-driving vehicle for driving decision making in real-time under any circumstances.
“The precise information processed and delivered by RS-LiDAR-M1 will help self-driving cars on making meaningful driving decisions based on sufficient redundant information. We are confident that the mass produced RS-LiDAR-M1 is necessary for SAE Level 3 to Level 5 of autonomous driving and ASIL-D advanced safety ”, said Mark, RoboSense COO & Co-founder.
The judges from AutoSens Awards review panel commented that RoboSense Smart LiDAR Sensor technology provides an innovative safety system to the industry, with a fusion of LiDAR sensor hardware and AI perception algorithm software. The judges deemed it a highly valuable system with strong innovation qualities.
The AutoSens Awards are the highlight of the global vehicle perception world. This year in Brussels, Belgium, it invites winners including start-ups, individuals and electronics and automotive giants, representing a thriving industrial ecosystem doing some of the most exciting technology development the world has ever seen. Its review panel consists of world-class experts in the field of automotive and attracts more than 120 participants. RoboSense is the final winner of “Best Automotive Safety System” category. The finalists include world-leading automotive brands as GM, Daimler, and FICOSA and Audi.
About RoboSense:
Founded in 2014, RoboSense (Suteng Innovation Technology Co., Ltd.) is the first and only MEMS-based Smart LiDAR Sensor for autonomous driving. RoboSense is headquartered in Shenzhen, China with branch offices in the U.S., Germany, Beijing, and Shanghai. Customers include the world’s leading autonomous driving technology companies, automotive OEMs, and Tier 1 suppliers.
For more information please visit: https://www.robosense.ai/
View source version on businesswire.com: https://www.businesswire.com/news/home/20190920005309/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom